A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02871479
• Other study ID #: SAN007-02
• Status: Completed
• Phase: Phase 2
• Start date: April 21, 2017
• Est. completion date: August 31, 2018

Study information

• Verified date: May 2019
• Source: Santalis Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28 days to patients at least 18 years of age, with atopic dermatitis.

Description:

Subjects will enter the Screening Period once the informed consent/ascent and photographic consent process has been completed. Subjects with a total body surface area (BSA) of ≥2% and ≤ 15% atopic dermatitis involvement, in the treatable areas, and who meet all of the inclusion and none of the exclusion criteria will be enrolled.

Once subject eligibility is confirmed and the screening procedures completed, the subject will start the Treatment Period of the study. All enrolled subjects will receive either 5% SAN007 cream or placebo cream (randomized in a 2:1 ratio) OR 10% SAN007 cream or placebo cream (randomized in a 2:1 ratio) with the first dose applied at Visit 1 Baseline. Subjects will be instructed on how to apply the study medication twice daily for 28 days. Subjects will return to the clinic on Study Days 7,14 and 28 for study-related assessments. Subjects will receive a telephone contact from the site, on Study Days 21 and 35.

Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.

In addition, cutaneous tolerability will be evaluated at each visit. Tolerability evaluation will be based on subjects reporting discomfort during or immediately following application of SAN007. This will also be recorded as an AE. The study exclusion areas are not to be included in this evaluation.

Efficacy will be assessed at each study visit through the completion of the IGA, EASI and BSA calculation.

During the active treatment period, subjects will return to the study site according to the study schedule for interim assessments and recording of concomitant medication and adverse events (AEs).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: August 31, 2018
• Est. primary completion date: August 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects will be included in the trial if they meet all of the following criteria:

1. Are at least 18 years of age

2. Have atopic dermatitis, as determined by an EASI score of =5 and =50 (Hanifin, 2001)

3. Total treatment area(s) of atopic dermatitis involvement =2% and =15% today surface area (BSA).

4. Have atopic dermatitis that has been clinically stable for = 30-days prior to the Screening Visit.

5. Are able to obtain written informed consent/ascent in a manner approved by the Institutional Review Board and comply with the requirements of the study.

6. Are willing to refrain from using any lotions, moisturizer, cleansers, cosmetics or creams, other than those issued as part of the study, on the target treatment areas during the treatment period.

7. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.

8. Are willing to refrain from exposure to artificial ultraviolet radiation for the duration of the study.

9. Are willing to cover target treatment areas to avoid exposure to natural ultraviolet radiation for the duration of the study.

10. If female of childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study. i.e. barrier method, hormone or intrauterine device.

11. Are willing to avoid participation in any other interventional clinical trial for the duration of this study.

12. Are willing to refrain from treating areas that are not in the defined treatment area(s), which will be excluded from the IGA assessments and BSA calculation. These areas are as follows: head, neck, soles of feet, palms of hands, axillae, or intertriginous areas.

Exclusion Criteria:

• Subjects will be excluded from the trial if they meet any of the following criteria:

1. Have a sibling or immediate family member already participating in this trial.

2. Currently requires and/or, in the 30 days prior to Screening, has required topical use of a medium or high potency steroid (i.e. >1%)

3. Atopic dermatitis that, in the opinion of the investigator, is likely to stem from an allergic reaction. (i.e. contact dermatitis)

4. Have <2% or >15% total BSA of atopic dermatitis involvement in the target treatment area(s).

5. Have participated in any interventional clinical trial in the previous 30 days to the screening visit.

6. Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.).

7. Have received phototherapy within the 60 days prior to Screening.

8. Have received any systemic medication for atopic dermatitis in the past 2 months that would interfere with the evaluation of atopic dermatitis (excluding antihistamines or leukotriene inhibitors).

9. Have a present condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

10. Are pregnant, breast-feeding or plan to become pregnant at any point for the duration of the trial.

11. Are not willing to practice an approved form of birth control while on the study drug for the duration of the trial. i.e. barrier method, hormone or intrauterine device.

12. Have been treated, with prescription medication for atopic dermatitis, within 60 days prior to the Baseline visit.

13. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years,or any other confounding skin condition.

14. Have undergone treatments with topical atopic dermatitis drug products, other than retinoids or corticosteroids, within 14 days prior to the Baseline Visit, and for therapy containing corticosteroids or retinoids within 28 days prior to Baseline Visit.

15. Have open sores or open lesions in the treatment area(s).

16. Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years.

17. Require greater than 2.0 mg/day inhaled or intranasal corticosteroids.

18. Have an active infection of any kind at Visit 1 (Baseline)

19. Have an occupation that requires =50% of time be spent outdoors, where prolonged exposure to ultraviolet radiation is unavoidable.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• SAN007 5% cream
5% EISO in a cream formulation applied twice a day for up to 28 days.
• Placebo
A placebo cream containing the same components as the vehicle for the active intervention arm
• SAN007 10% cream
10% EISO in a cream formulation applied twice a day for up to 28 days.

Locations

Country	Name	City	State
United States	DermResearch	Austin	Texas
United States	J&S Sudies Pharmaceutical	Bryan	Texas
United States	Clinical Trials of Texas	San Antonio	Texas
United States	Progressive Clinical Research	San Antonio	Texas
United States	Texas Dermatology and Laser Specialists	San Antonio	Texas

Sponsors (7)

Lead Sponsor	Collaborator
Santalis Pharmaceuticals, Inc.	ClinDatrix, Inc., Clinical Trials of Texas, Inc., Derm Research, PLLC, Progressive Clinical Research, Texas Dermatology and Laser Specialists, U.S. Dermatology Partners Bryan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Adverse Events	Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.	28 days
Secondary	Percentage of Subjects Who Have a = 50% Reduction in the Eczema Area and Severity Index (EASI) Score	Percentage of subjects who have a = 50% reduction in the Eczema Area and Severity Index (EASI) score at any point during the trial. Minimum value is a 0 and a maximum value is 72. Higher score denoting worse than a lower score.	28 days